Clinical trialNCT06352359RecruitingPhase 1Interventional

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

SponsorOncoC4, Inc.Enrollment72Advanced Solid Tumor

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose expansion in the last dose level. The Phase 2 part will test the combination of ONC-841 with SOC in GBM and in CRC.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Tianhong Li, MD, PhD
University of California, Davis
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California at Davis Cancer Center
Sacramento, California, United States
Recruiting
Uf Health Cancer Center, University of Florida
Gainesville, Florida, United States
Recruiting
Adventhealth Medical Group Oncology Research at Celebration
Kissimmee, Florida, United States
Recruiting
Norton Cancer Center
Louisville, Kentucky, United States
Recruiting
Rogel Cancer Center, University of Michigan
Ann Arbor, Michigan, United States
Recruiting
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Recruiting
Md Anderson Cancer Center
Houston, Texas, United States
Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

ONC-841

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 23 Aug 2024
Primary completion: 30 Sept 2027
Completion: 30 Sept 2027
Last update posted: 25 Jun 2026
Registered enrollment: 72
Registry id: NCT06352359

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.